Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.

被引：2
|
作者：
Mhanna, Laurent
Milia, Julie
Lusque, Amellie
Couraud, Sebastien
Mascaux, Celine
Veillon, Remi
Frueh, Martin
Moro-Sibilot, Denis
Lattuca-Truc, Mickael
Tomasini, Pascale
Barlesi, Fabrice
Drilon, Alexander E.
Gautschi, Oliver
Mazieres, Julien
机构：
[1] Univ Hosp Toulouse Larrey, Toulouse, France
[2] Ctr Hosp Univ Toulouse, Hop Larrey, Toulouse, France
[3] Inst Univ Canc Toulouse Oncopole Cellule Biostat, Bur Essais Clin, Toulouse, France
[4] Lyon Sud Hosp, Acute Resp Med & Thorac Oncol Dept, Pierre Benite, France
[5] Lyon Univ, Canc Inst, Pierre Benite, France
[6] Aix Marseille Univ, Aix En Provence, France
[7] Assistance Publ Hop Marseille, Marseille, France
[8] Hop Haut Leveque, Pessac, France
[9] Cantonal Hosp St Gallen, St Gallen, Switzerland
[10] CHU Grenoble, IFCT, Grenoble, France
[11] Univ Hosp Grenoble, Grenoble, France
[12] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[13] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France
[14] Mem Sloan Kettering Canc Ctr, New York, NY USA
[15] Cantonal Hosp Lucerne, Luzern, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 05期
关键词：
D O I：
10.1200/JCO.2018.36.5_suppl.172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
172
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).
    Mazieres, Julien
    Drilon, Alexander E.
    Mhanna, Laurent
    Milia, Julie
    Lusque, Amellie
    Cortot, Alexis B.
    Mezquita, Laura
    Thai, Alesha
    Couraud, Sebastien
    Veillon, Remi
    Mascaux, Celine
    Schouten, Robert
    Neal, Joel W.
    Ng, Terry L.
    Frueh, Martin
    Peled, Nir
    Gounant, Valerie
    Popat, Sanjay
    Zhu, Viola Weijia
    Gautschi, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)
    Mazieres, J.
    Tomasini, P.
    Lusque, A.
    Boucekine, M.
    Gautschi, O.
    Cortot, A. B.
    Couraud, S.
    Thai, A.
    Ng, T.
    Greillier, L.
    Veillon, R.
    Neal, J. W.
    Popat, S.
    Gounant, V.
    Mhanna, L.
    Drilon, A.
    Baron, J. Milia
    Barlesi, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S826 - S827
  • [3] Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
    Qiao, Meng
    Zhou, Fei
    Hou, Likun
    Li, Xuefei
    Zhao, Chao
    Jiang, Tao
    Gao, Guanghui
    Su, Chunxia
    Wu, Chunyan
    Ren, Shengxiang
    Zhou, Caicun
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (01)
  • [4] Impact of Corticosteroids and Antibiotics on Efficacy of Immune-Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
    Riudavets, M.
    Mosquera, J.
    Garcia Campelo, R.
    Serra, J.
    Anguera, G.
    Gallardo, P.
    Sullivan, I. G.
    Barba, A.
    Majem, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S728 - S728
  • [5] Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC)
    Meisel, A.
    Mark, M. T.
    Haider, A.
    Holer, L.
    Hayoz, S.
    Gebhard, C.
    Bengs, S.
    Treyer, V.
    Rothschild, S. I.
    Hochmair, M. J.
    Gandara, D. R.
    Cappuzzo, F.
    Reck, M.
    Stenner-Liewen, F.
    Von Moos, R. A. F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1035 - S1036
  • [6] Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated
    De Giglio, A.
    Mezquita, L.
    Auclin, E.
    Blanc-Durand, F.
    El-Amarti, L.
    Caramella, C.
    Bernal, G. Martinez
    Hendriks, L.
    Ferrara, R.
    Naltet, C.
    Lavaud, P.
    Gazzah, A.
    Adam, J.
    Planchard, D.
    Chaput, N.
    Besse, B.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection
    Banna, Giuseppe Luigi
    Passiglia, Francesco
    Colonese, Francesca
    Canova, Stefania
    Menis, Jessica
    Addeo, Alfredo
    Russo, Antonio
    Cortinovis, Diego Luigi
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 129 : 27 - 39
  • [8] The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations
    Sakamoto, Hiroaki
    Tanaka, Hisashi
    Shiratori, Toshihiro
    Baba, Keisuke
    Ishioka, Yoshiko
    Itoga, Masamichi
    Taima, Kageaki
    Hasegawa, Yukihiro
    Takanashi, Shingo
    Tasaka, Sadatomo
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (06) : 610 - 614
  • [9] Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
    Wang, Haowei
    Cheng, Lei
    Zhao, Chao
    Zhou, Fei
    Jiang, Tao
    Guo, Haoyue
    Shi, Jinpeng
    Chen, Peixin
    Tang, Zhuoran
    Mao, Shiqi
    Jia, Keyi
    Ye, Lingyun
    Cai, Chenlei
    Li, Xuefei
    Chen, Xiaoxia
    Zhou, Caicun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 219 - +
  • [10] Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Hendriks, L.
    Henon, C.
    Auclin, E.
    Mezquita, L.
    Ferrara, R.
    Audigier-Valette, C.
    Mazieres, J.
    Lefebyre, C.
    Le Moulec, S.
    Cousin, S.
    Duchemann, B.
    Le Pechoux, C.
    Botticella, A.
    Ammari, S.
    Gazzah, A.
    Caramella, C.
    Adam, J.
    Planchard, D.
    De Ruysscher, D.
    Dingemans, A.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S384 - S384
12345